A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, Immunogenicity, and Pharmacodynamics of Eculizumab (SB12, EU Sourced Soliris, and US Sourced Soliris) in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs Eculizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Pharmacokinetics
- Sponsors Samsung Bioepis
- 04 Apr 2019 Status changed from recruiting to completed.
- 18 Nov 2018 Status changed from not yet recruiting to recruiting.
- 02 Nov 2018 New trial record